Related Experiment Videos
Physiopathology of premature progesterone elevation
R Fanchin1, D de Ziegler, V D Castracane
1Hôpital Antoine Béclère, Clamart, France.
Fertility and Sterility
|October 1, 1995
Summary
The last human menopausal gonadotropin (hMG) injection in controlled ovarian hyperstimulation (COH) for in vitro fertilization-embryo transfer (IVF-ET) significantly increases progesterone and androgen levels. This hormonal surge may impact endometrial receptivity in some women undergoing IVF-ET.
Area of Science:
- Reproductive Endocrinology
- In Vitro Fertilization
Background:
- Controlled ovarian hyperstimulation (COH) is a key component of in vitro fertilization-embryo transfer (IVF-ET).
- Human menopausal gonadotropin (hMG) is commonly used in COH protocols.
- The hormonal milieu during COH can influence treatment outcomes.
Purpose of the Study:
- To investigate the impact of the final hMG administration on plasma progesterone (P) and androgen profiles.
- To understand the temporal dynamics of hormonal changes following hMG in COH for IVF-ET.
Main Methods:
- A controlled clinical study was conducted in an IVF-ET program.
- Nine women undergoing COH for IVF-ET received a standard hMG protocol.
- Serial blood sampling was performed for 24 hours post-final hMG administration to measure various hormones.
Main Results:
- Plasma progesterone and androgens (testosterone and androstenedione) significantly increased after hMG, peaking at 12-15 hours.
- Estradiol levels showed a progressive increase throughout the 24-hour period.
- Follicle-stimulating hormone (FSH) levels remained stable, while luteinizing hormone (LH) was undetectable post-hMG.
Conclusions:
- The last hMG injection in COH for IVF-ET induces a significant, transient rise in plasma progesterone and androgens.
- This hormonal increase is likely due to the direct action of LH and/or FSH components of hMG on granulosa cells.
- The observed hormonal changes may potentially affect endometrial receptivity in some patients undergoing IVF-ET.